Isomorphic Labs, an AI-driven drug discovery startup, has raised $600 million in its first-ever external funding round, led by Thrive Capital, the company announced on Monday.
With tech giants increasingly integrating AI-powered solutions into their products, startups specializing in generative AI and machine learning continue to attract strong investor interest.
Founded in 2021 as a spin-off from Alphabet’s AI research arm, Google DeepMind (acquired in 2014), Isomorphic Labs has made significant strides in AI-powered drug discovery. Last May, it introduced the third major version of its Nobel Prize-winning AlphaFold model, which accurately predicts almost all known protein structures.
The London-based startup plans to utilize the newly raised capital to accelerate R&D efforts and expand its talent pool.
CEO and Founder Demis Hassabis, who also heads DeepMind, hinted in January that AI-designed drugs developed by Isomorphic Labs could enter clinical trials by late 2025.
Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!
